Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics

Journal of Affective Disorders

Volumn 48, Issue 2-3, 1998, Pages 91-104

  Frye, Mark A ^a   Ketter, Terence A ^b   Altshuler, Lori L ^c   Denicoff, Kirk ^a   Dunn, Robert T ^a   Kimbrell, Timothy A ^a   Corá Locatelli, Gabriela ^a   Post, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bipolar disorder; Clozapine; Neuroleptics

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE; TRIMIPRAMINE;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLOZAPINE; HUMANS; IMIDAZOLES; INDOLES; PIRENZEPINE; RISPERIDONE; TRIMIPRAMINE;

EID: 0031750352     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(97)00160-2     Document Type: Article

References (148)

1. Ahlfors U.G., Baastrup P.C., Denker S.J., Elgen K., Lingjaerde O., Pedersen V., Schou M. Flupenthixol Decanoate in recurrent manic depressive illness (A comparison with lithium). Acta Psychiatr. Scand. 64:1981;226-237.
2. Antonacci D.J., Swartz C.M. Clozapine treatment of euphoric mania. Ann. Clin. Psychiatry. 7:1995;203-206.
3. Baker R., Ames D., Umbricht D., Chengappa K.N.R., Schooler N.R. Olanzapine's impact on depressive and obsessive-compulsive symptoms in schizophrenia. Psychopharmacol. Bull. 31:1995;549.
4. Baldessarini R.J., Frankenburg F.R. Clozapine A novel antipsychotic agent. New Engl. J. Med. 324:1991;746-754.
5. Banov M.D., Zarate C.A., Tohen M., Scialabba D., Wines J.D. Jr., Kolbrener K.J.W., Cole J.O. Clozapine therapy in refractory affective disorders: polarity predicts response in long term follow up. J. Clin. Psychiatry. 55:1994;295-300.
6. Barkin J.S., Pais V.M. Induction of mania by risperidone resistant to mood stabilizers. J. Clin. Psyhcopharmacol. 17:1997;56-57.
7. Battegay R., Cotar B., Fleischhauer J., Rauchfleisch U. Result and side effects of treatment with clozapine (Leponex R). Compr. Psychiatry. 18:1977;423-438.
8. Beasley, C.M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., Hamilton, S., the Olanzapine HGAD Study Group, 1996. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 14, 111-123.
9. Bender, S., Olbrich, H., Schöne, W., Falkai, P., for the Trimipramine Study Group, 1997. Antipsychotic efficacy of the antidepressant trimipramine: double blind compariosn with the phenothiazine perazine. Biol. Psychiatry 42, 231S.
10. Berger M., Gastpar M. Trimipramine: a challenge to current concepts on antidepressives. Eur. Arch. Psychiatry Clin. Neurosci. 246:1996;235-239.
11. Brunello N., Masotto C., Steardo L., Markstein R., Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 13:1995;177-213.
12. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C.et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
13. Calabrese J.R., Kimmel S.E., Woyshville M.J., Rapport D.J., Faust C.J., Thompson P.A.et al. Clozapine for treatment refractory mania. Am. J. Psychiatry. 153:1996;759-764.
14. Calabrese J.R., Meltzer H.Y., Markovitz P.J. Clozapine prophylaxis in rapid cycling bipolar disorder. J. Clin. Psychopharmacol. 11:1991;396-397.
15. Chakos M.H., Lieberman J.A., Alvir J., Bilder R., Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics and clozapine. Lancet. 345:1995;456-457.
16. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogarts B.et al. Increase in caudate nuclei volumes of first episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry. 151:1994;1430-1436.
17. Chiodo L.A., Bunney B.S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. 5:1985;2539-2544.
18. Chouinard G., Jones B.D. Neuroleptic induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am. J. Psychiatry. 137:1980;16-21.
19. Chouinard G., Jones B.D., Remington G., Bloom D., Addington D., MacEwan G.W.et al. A Canadian Multicenter Placebo-controlled study of fixed doses of risperidone and haloperidol in treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
20. Cole J., Gardos G., Boling L.A., Marby D., Haskell D., Moore P. Early dyskinesia-vulnerability. Psychopharmacology. 107:1992;503-510.
21. Daniel, D., Targum, S., Zimbroff, D., Mack, R., Zborowski, J., Morris, D., Sebree, T., Walin, B., 1995. Efficacy, safety, and dose response of three doses of sertindole and three doses of haloperidol in schizophrenic patients. Abstract, Meeting of the American College of Neuropsychopharmacology December 10-15.
22. Dassa D., Kaladjian A., Azorin J.M., Giudicelli S. Clozapine in the treatment of psychotic refractory depression. Br. J. Psychiatry. 163:1993;822-824.
23. Denicoff, K.D., Smith-Jackson, E.E., Disney, E.R., Ali, S.O., Leverich, G.S., Post, R.M., 1997. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J. Clin. Psychiatry, in press.
24. Denney D.D., Stevens J.R. Clozapine and seizures. Biol. Psychiatry. 37:1995;427-433.
25. Deutch A.Y., Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience. 46:1992;49-56.
26. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on prefrontal cortical Fos expression: cellular localization and pharmacological characterization. Neuroscience. 70:1996;377-389.
27. Deutch A.Y. Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. J. Clin. Psychiatry. 55:1994;B37-42.
28. Diaz S.F. Mania associated with risperidone. J. Clin. Psychiatry. 57:1996;41-42.
29. Dunner D.L., Fieve R.R. Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. Psychiatry. 30:1974;229-233.
30. Dwight M.M., Keck P.E. Jr., Stanton S.P., Strakowski S.M., McElroy S.L. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder [letter]. Lancet. 344(8921):1994;554-555.
31. Eikmeier G., Berger M., Lodemann E., Muszynski K., Kaumeier S., Gastpar M. Trimipramine - an atypical neuroleptic? International Clinical Psychopharmacology. Winter. 6:1991;147-153.
32. Eli Lilly, Zyprexa® package insert, 1996.
33. Faedda G.L., Baldessarini R.J., Tohen M., Strakowski S.M., Waternaux C. Episode sequence in bipolar disorder and response to lithium treatment. Am. J. Psychiatry. 148:1991;1237-1239.
34. Farde L., Mack R.J., Nyberg S., Halldin C. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int. Clin. Psychopharmacol. 12(suppl):1997;S3-S7.
35. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission topography analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry. 49:1992;538-544.
36. Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone treated schizophrenic patients. J. Clin. Psychopharmcol. 15:1995;19S-23S.
37. Farde L., Wiesel F.A., Nordstrom A.L., Sedvall G. D1 and D2 dopamine receptor occupancy during treatment with conventional and typical neuroleptics. Psychopharmacology. 99s:1989;28-31.
38. Fink-Jensen A., Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci. Lett. 182:1994;115-118.
39. Fleischhacker W.W., Hummer M., Kurz M., Kurzthaler I., Lieberman J.A., Pollack S.et al. Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects. J. Clin. Psychiatry. 55 56 57 58 59(Suppl. B):1994;78-81.
40. Frankenburg F.R. Clozapine and bipolar disorder. J. Clin. Psychopharmacol. 13:1993;289-290.
41. Frye, M.A., Altshuler, L.L., 1997. Selection of initial treatment for bipolar disorder, manic phase. In: Rush, A.J. (Ed.), Clinical Decision Trees in the Pharmacotherapy of Mood Disorders. Karger Book Series: Modern Problems in Pharmacopsychiatry, Basel Karger, vol 25. pp 88-113.
42. Frye M.A., Altshuler L.L., Bitran J. Clozapine in rapid cycling bipolar disorder. J. Clin. Psychopharmacol. 16:1996;87-91.
43. Frye, M.A., Ketter, T.A., Leverich, G., Denicoff, K., Kimbrell, T.A., Little, J., Corá-Locatelli, G., Post, R.M., 1996. Rational Polypharmacy in Manic Depressive Illness. Annual Meeting of the American Psychiatric Association, May 4-9, New York.
44. Fuchs C.D. Clozapine treatment of bipolar disorder in a young adolescent. J. Am. Acad. Child Adolesc. Psychiatry. 33:1994;1299-1302.
45. Gardos G., Teicher M.H., Lipinski L.F. Jr., Matthews J.D., Morrison L., Conley C.et al. Quantitative Assessment of psychomotor activity in patients with neuroleptic induced akathisia. Prog. Neuropsychopharmacol. 16:1992;27-37.
46. Garfinkel P.E., Stancer H.C., Persad E. A comparison of haloperidol, lithium carbonate, and their combination in the treatment of mania. J. Affect. Disord. 2:1980;279-288.
47. Gelenberg A.J., Hopkins H.S. Antipsychotics in bipolar disorder. J. Clin. Psychiatry. 57S:1996;49-52.
48. George M.S., Ketter T.A., Post R.M. Prefrontal cortex dysfunction in clinical depression. Depression. 2:1994;59-72.
49. Ghaemi S.N., Sachs G., Baldassano C.F., Truman C.J. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can. J. Psychiatry. 42:1997;196-199.
50. Gitlin M.J., Swendsen J., Heller T.L., Hammen C. Relapse and impairment in bipolar disorder. Am. J. Psychiatry. 152:1995;1635-1640.
51. Glenthoj B., Hemmingsen R., Asserup P., Bolwig T.G. Intermittent versus continuous neuroleptic treatment in a rat model. Eur. J. Pharmacol. 190:1990;275-286.
52. Goldberg J.F., Harrow M., Sands J.R. Lithium and the longitudinal course of bipolar illness. Psychiatr. Ann. 26:1996;651-658.
53. Goodnick P.J. Risperidone treatment of refractory acute mania. J. Clin. Psychiatry. 56:1995;431-432.
54. Goodwin, F.K., Jamison, K.R., 1990. Manic-Depressive Illness. Oxford University Press, New York.
55. Harma B.J., Nasrallah H.A., Clancy J., Finn R. Psychiatric diagnosis and risk for tardive dyskinesia. Arch. Gen. Psychiatry. 40:1983;346-347.
56. Heinrich K., Klieser E., Lehmann E., Kinzler E., Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog. Neuropsychopharmacol. 18:1994;127-137.
57. Hendrik V., Altshuler L.L., Szuba M.P. Is there a role for neuroleptics in bipolar depression? J. Clin. Psychiatry. 55:1994;533-535.
58. Hillert A., Maier W., Wetzel H., Benkert O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome - a functional approach. Pharmacopsychiatry. 25:1992;213-217.
59. Himmelhoch J.M., Garfinkel M.E. Mixed mania: diagnosis and treatment. Psychopharmacol. Bull. 22:1986;613-620.
60. Hirschfeld R.M.A. Schizoaffective Disorder and Psychotic Mania. Psychiatr. Ann. 26:1996;S435-439.
61. Jacobsen F.M. Risperidone in the treatment of severe affective illness and refractory OCD. J. Clin. Psychiatry. 56:1995;423-429.
62. Jeste, D.V., Wyatt, R.J., 1982. Understanding and treating tardive dyskinesia. Guilford Press, New York.
63. Kando J.C., Tohen M., Castillo J., Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J. Clin. Psychiatry. 55:1994;255-257.
64. Kane, J.M., Honigfeld, G., Singer, J., Meltzer, H., the Clozapine Collaborative Study Group, 1988. Clozapine and the treatment resistant schizophrenic. Arch Gen Psychiatry 45, 789-796.
65. Kane J.M., Woerner M., Borenstein M., Wegner J., Lieberman J.A. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol. Bull. 22:1986;254-258.
66. Keck, P.E., Wilson, D.R., Strakowski, McElroy, S.L., Kizer, D.L., Balestreri, A., 1995. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 56, 466-470.
67. Keck P.E., McElroy S.L., Strakowski S.M., Balistreri T.M., Kizer D.L., West S.A. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J. Clin. Psychiatry. 57:1996;147-151.
68. Keshaven M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., Pettegrew J.W. Changes in caudate volume with neuroleptic treatment. Lancet. 344:1994;1434.
69. Koek R.J., Kessler C.C. Probable induction of mania by risperidone. J. Clin. Psychiatry. 57:1996;174-175.
70. Kraepelin, E., 1990. Manic Depressive Insanity and Paranoia. Reprint of the 1921 edition. Ayer Company, Publishers.
71. Kronig, M.H., Munne, R.A., Szymanski, S., Safferman, A.Z., Pollack, Cooper, T., Kane, J.M., 1995. Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am. J. Psychiatry 152, 179-182.
72. Lee, A.M., Knoll, J.L., Suppes, T., 1997. The atypical antipsychotic sertindole: a case series. J. Clin. Psychiatry, in press.
73. Leppig M., Bosch B., Naber D., Hippius H. Clozapine in the treatment of 121 outpatients. Psychopharmacology. 99:1989;S77-S79.
74. Leysen J.E., Janssen P.M.F., Megens A.A.H., Schotte A. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry. 55:1994;5S-12S.
75. Lindstrom L.H. The effect of long term treatment with clozapine in schizophrenia retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr. Scand. 77:1988;524-529.
76. Madhusoodanan S., Brenner R., Araujo L., Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia 11 geriatric patients: a case series. J. Clin. Psychiatry. 56:1995;514-518.
77. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
78. Marder S.R., Van Putten T. Who should receive clozapine? Arch. Gen. Psychiatry. 45:1988;865-867.
79. McElroy S.L., Dessain E.C., Pope H.G., Cole J.O., Keck P.E., Frankenberg F.R.et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry. 52:1991;411-414.
80. Meltzer H. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
81. Meltzer H. Dimensions of outcome with clozapine. Br. J. Psychiatry. 160(17, suppl):1992;46-53.
82. Meltzer H.Y., Kennedy J., Dai J., Parsa M., Riley D. Plasma clozapine levels and the treatment of L dopa induced psychosis in Parkinson's disease: a high potency effect of clozapine. Neuropsychopharmacology. 12:1995;39-45.
83. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3:1995;64-75.
84. Miller D.D., Fleming F., Holman T.L., Perry P.J. Plasma clozapine concentrations as predictor clinical response: a follow up study. J. Clin. Psychiatry. 55:1994;B117-121.
85. Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double blind parallel group study vs. haloperidol. The International Risperidone Research Group. Clin Neuropharmacol. 15(Suppl 1):1992;90A-91A.
86. Mukherjees S., Rosen A.M., Caracci G., Shukle S. Persistent tardive dyskinesia in bipolar patients. Arch. Gen. Psychiatry. 43:1986;342-346.
87. Naber B., Hippius H. The European experience with use of clozapine. Hosp. Community Psychiatry. 41:1990;886-890.
88. Naber D., Holzbach R., Hippius H. Clinical management of clozapine patients in relation to efficacy and side effects. Br. J. Psychiatry. 160:1992;54-59.
89. Naber D., Leppig M., Grohmann R., Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology. 99:1989;S73-S76.
90. Nahunek K., Rodova J., Svestka V., Kamenicka V., Ceskova E., Misurec J. Clinical experience with clozapine in endogenous depression. Activ. Nerv. Sup. (Praha). 2:1973;15.
91. Nasrallah H.A., Churchill C.M., Hamden-Allan G.A. Higher frequency of neuroleptic induced dystonia in mania than in schizophrenia. Am. J. Psychiatry. 145:1988;1455-1456.
92. Nyberg S., Farde L., Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
93. O'Connell R.A., Mayo J.A., Flatow L., Cuthbertson B., O'Brien B.E. Outcome of bipolar disorder on long term treatment with lithium. Br. J. Psychiatry. 159:1991;123-129.
94. O'Croinin Z.T., Holt L. Hypomania associated with risperidone. Can. J. Psychiatry. 2:1995;51.
95. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
96. Owen R.R., Beake B.J., Marby D., Dessain E., Cole J.O. Response to clozapine in chronic psychotic patients. Psychopharmacol. Bull. 25(2):1989;253-256.
97. Patel, J.K., Green, A.I., Banov, M.D., Tohen, M., Schatzberg, A., Cole, J.O., 1995. Clozapine use in treatment refractory mania and psychosis. Presented at the 148 th Annual Meeting of the American Psychiatric Association May 20-25, Miami, Florida.
98. Peacock L., Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and Hematologic monitoring in a system with liberal usage practices. J. Clin. Psychiatry. 55:1994;44-49.
99. Peselow E.D., Fieve R.R., Difiglia C., Sanfilipo M.P. Lithium prophylaxis of bipolar illness: the value of combination treatment. Br. J. Psychiatry. 164:1994;208-214.
100. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., Rapaport M. Clinical and biologic response to clozapine in patients with schizophrenia-crossover comparison with fluphenazine. Arch. Gen. Psychiatry. 49:1992;345-353.
101. Pillay S.S., Stoll A.L., Weiss M.K., Tohen M., Zarate C.A., Banov M.D., Cole J.P. EEG Abnormalities before clozapine therapy predict a good clinical response to clozapine annals. Clinical Psychiatry. 8:1996;1-5.
102. Post R.M., Ketter T.A., Denicoff K., Pazzaglia P.J., Leverich G.S., Marangell L.et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology. 128:1996;115-129.
103. Post, R.M., 1986. Does limbic system dysfunction play a role in affective illness? In: Doane, B.K., Livingston, K.E. (Eds.), The limbic system: functional organization and clinical disorders. Raven Press, New York.
104. Povlsen U.J., Noring U., Berlach J. Tolerability and therapeutic effect of clozapine. Acta Psychitr. Scand. 71:1985;176-185.
105. Prien R.F., Gelenberg A.J. Alternatives to Lithium for Preventive Treatment of Bipolar Disorder. Am. J. Psychiatry. 146:1989;840-848.
106. Privitera M.R., Lamberti J.S., Maharaj K. Clozapine in a bipolar depressed patient. Am. J. Psychiatry. 150:1993;986.
107. Puri B.K., Taylor D.G., Alcock M.E.C. Low dose maintenance clozapine treatment in the prophylax is of bipolar affective disorder. British Journal Clinical Pharmacology. 49:1995;333-334.
108. Raitasuo V., Lehtovaara R., Huttunen M.O. Carbamazepine and plasma levels of clozapine. Am. J. Psychiatry. 150:1993;169.
109. Rao T.S., Contreras P.C., Cler J.A., Emmett M.R., Mick S.J., Iyengar S.et al. Clozapine attenuates NMDA receptor complex mediated responses in vivo: tentative evidence for a functional modulation by a noradrenergic mechanism. Neuropharmacology. 30:1991;557-565.
110. Ranjan R., Meltzer H.Y. Acute and long term effectiveness of clozapine in treatment resistant psychotic depression. Biol. Psychiatry. 40:1995;253-258.
111. Risby E.D., Epstein C.M., Jewart R.D., Nguyen B.V., Morgan W.N., Risch S.C.et al. Fall. Clozapine-induced EEG abnormalities and clinical response to clozapine. J. Neuropsychiatry Clin. Neurosci. 7:1995;466-470.
112. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
113. Robertson G.S., Fibiger H.C. Neuroleptics increase c fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
114. Roose K., Gelders Y., Heylen S. Risperidone (R 64 766) in psychotic patients: a first clinical therapeutic experience. Acta Psychiatr. Belg. 88:1988;233-241.
115. Sachs G.S. Use of clonazepam for bipolar affective disorder. J. Clin. Psychiatry. 51(5, suppl):1990;31-34.
116. Safferman A., Lieberman J.A., Kane J.M., Szymanski S., Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr. Bull. 17:1991;247-261.
117. Sager S.M., Sharp F.R., Curran T. Expression of c fos protein in brain: metabolic mapping at the cellular level. Science. 240:1988;1328-1331.
118. Sajatovic M., DiGiovanni S.K., Bastani B., Hattab H., Ramirez L.F. Risperidone therapy in treatment refractory, acute bipolar, and schizoaffective mania. Psychopharmacol. Bull. 32:1996;55-61.
119. Schaffer C.B., Schaffer L.C. The use of risperidone in the treatment of bipolar disorder. J. Clin. Psychiatry. 57:1996;136.
120. Shulman R.W., Singh A., Shulman K.I. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol. Bull. 33:1997;113-118.
121. Seeman P. Dopamine receptor sequences, therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7:1992;261-284.
122. Sernyak M.J., Godleski L.S., Griffin R.A., Mazure C.M., Woods S.W. Chronic neuroleptic exposure in bipolar outpatients. J. Clin. Psychiatry. 58:1997;193-195.
123. Sernyak M.J., Woods S.W. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol. Bull. 29:1993;375-381.
124. Settle E.C. Jr., Ayd F.R. Jr. Trimipramine: twenty years' worldwide experience. J. Clin. Psychiatry. 41:1980;266-274.
125. Singh A.N., Catalan J. Risperidone in HIV-related main psychosis. Lancet. 344:1994;1029-1030.
126. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse. 10:1992;25-33.
127. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotics drugs on the activity of midbrain dopamine neurons in the rat. Eur. J. Pharmacol. 281:1995;289-294.
128. Small J.G., Milstein V., Marhenke J.D., Hall D.D., Kellams J.J. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment resistant psychosis. J. Clin. Psychiatry. 48:1987;263-267.
129. Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 14:1996;97-104.
130. Suppes T., McElroy S., Gilbert J., Dessain E., Cole J. Clozapine in the treatment of dysphoric mania. Biol. Psychiatry. 32:1992;270-280.
131. Suppes T., Phillips K.A., Judd C.R. Clozapine treatment of non-psychotic rapid cycling bipolar disorder: a report of three cases. Biol. Psychiatry. 36:1994;338-340.
132. Suppes T., Rush A.J., Webb A., Carmody T., Kraemer H. A One year randomized trial of clozapine vs. usual care in bipolar I patients. Biol. Psychiatry. 39:1996;531.
133. Tohen M., Waternaux C.M., Tsuang M.T., Hunt A.T. Four year follow-up of 24 first episode manic patients. J. Affect. Disord. 19:1990;79-86.
134. Tohen, M., Zarate, C.A., Centorrino, F., Hegarty, J., Froeschl, Zarate, S.M., 1996. Risperidone in the treatment of mania. J. Clin. Psychiatry 57, 249-253.
135. Tohen, M., Sanger, T., Tollefson, G.D., McElroy, S.L., 1997. Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients. Annual Meeting of the American Psychiatric Association, May 17-22, San Diego California.
136. Tomlinson C.W. Risperidone and mania. Am. J. Psychiatry. 153:1996;132-133.
137. Van Kammen, D.P., McVay, J.P., Targum, S.D., Kardatzke, D., Sebree, T.B., the Sertindole Study Group, 1996. A randomized controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124, 168-175.
138. Van Praag H.M., Korf J., Dols L.C.W. Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. Br. J. Psychiatry. 129:1976;547-555.
139. Van Putten T., May P.R.A., Marder S., Wittmann L. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry. 38:1981;187-190.
140. Verdoux H., Gonzales B., Takei N., Bourgeois M. A survey of prescribing practice of antipsychotic treatment for manic-depressive outpatients. J. Affect. Disord. 38:1996;81-87.
141. Vestergaard P. Treatment and Prevention of Mania: A Scandinavian Perspective. Neuropsychopharmacology. 7:1992;249-259.
142. White F.J., Wang R.Y. Comparison of the effects of chronic haloperidol on A9 and A10 dopamine neurons in rat. Life Sci. 32:1983;983-993.
143. Wilson W.H. Do anticonvulsants hinder clozapine treatment? Biol. Psychiatry. 37:1995;132-133.
144. Wirshing C.W., Ames D., Bisheff S., Pierre J.M., Mendosa A., Sun A. Hepatic encephalopathy associated with combined clozapine divalproex sodium treatment. J. Clin. Psychopharmacol. 17:1997;120-121.
145. Wood M.J., Rubenstein M. An atypical response to clozapine. Am. J. Psychiatry. 147(3):1990;369.
146. Zarate C.A., Tohen M., Baldessarini R.J. Clozapine in severe mood disorders. J. Clin. Psychiatry. 56:1995;411-417.
147. Zarate C.A., Tohen M., Banov M., Weiss M.K., Cole J.D. Is Clozapine a mood stabilizer? J. Clin. Psychiatry. 56:1995;108-112.
148. Zarate, C.A., Narendran, R., Tohen, M., Greaney, J.J., Berman, A., Pike, S., Madrid, A., 1997. Clinical predictors of acute response with olanzapine in psychotic mood disorders. Annual Meeting of the American Psychiatric Association, May 17-22, San Diego California.